$ORIC

Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush

Wedbush has reaffirmed its "Outperform" rating for Oric Pharmaceuticals (ORIC) with a $20.00 price target, implying an 81.9% upside. This comes after the company recently surpassed quarterly EPS estimates. Despite some insider selling, institutional investors have increased their stakes, holding 95.05% of the company's stock.

Original reporting
MarketBeat · MarketBeat
Published Dec 8, 2025, 3:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 8, 2025, 4:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush — source image
Decision brief

The 30-second read

$ORICBullishHigh
01

Why it matters

The reaffirmed rating and increased institutional holdings suggest strong confidence in the company's growth prospects, likely supporting stock price appreciation.

02

Market read

The news is highly relevant for traders focusing on biotech stocks, especially those with recent earnings surprises and analyst upgrades.

03

What to watch

Potential volatility due to upcoming clinical trial results or regulatory decisions; broader market corrections could temper gains.

Timing: immediate to short-term (next 1-3 months)

Background

Oric Pharmaceuticals recently exceeded quarterly EPS estimates, attracting analyst upgrades and institutional interest.

Company-level read

Ticker impact

$ORICBullishHigh confidence
Context

Primary focus of the news, relevant for short-term and medium-term trading strategies.

Expected impact

Potential upward movement in ORIC stock price, possibly 10-15% in the short term, contingent on market conditions.

Evidence & confidence

The reaffirmed rating, high institutional interest, and positive earnings surprise collectively suggest a strong bullish sentiment and potential price appreciation.

Market effects

Positive sentiment for biotech and life sciences sectors, especially companies with similar growth profiles or recent earnings surprises.

Limited regional impact; primarily relevant to US markets where ORIC is listed.

Moderate; biotech sector trends can influence global biotech indices but are less impactful on broader markets.

Counterpoint

Some skepticism remains due to insider selling activity, which could indicate profit-taking or caution among insiders.

Key entities

  • Wedbush

    Major investment bank reaffirming the 'Outperform' rating for ORIC.

  • Institutional Investors

    Hold 95.05% of ORIC stock, indicating strong backing.

  • Oric Pharmaceuticals

    Biotech firm focused on developing targeted therapies.

Related articles

$ORICMed

Oric Pharmaceuticals, Inc. (ORIC): Results of Operations and Financial Condition

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oric-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.